GSK’s Pandemrix Swine Flu Vaccine: Pandora's Box Release
0 views
Skip to first unread message
news....@googlemail.com
Sep 28, 2009, 4:12:33 AM9/28/09
to omeg...@googlegroups.com
GSK’s
Pandemrix Swine Flu Vaccine - Pandora's Box Release
60 million doses GlaxoSmithKline’s ‘Pandemrix’ H1N1 Swine Flu vaccine are shortly to be let out of the box and guinea pig trialled on the UK population including babies as young as 6 months and pregnant women. One Click publishes GSK's Pandemrix Vaccine Patent filed in 2006, together with the vaccine's CHMP Report and Product Information. These show that largely untested and untrialled, the vaccine contains the thimerosal and squalene adjuvants over which much concern has been raised. Serious adverse events on this vaccine were reported but not detailed. To date there have only been 80 swine-flu related deaths in the UK in 2009 and in general, symptoms are not severe. It is irresponsible, unsafe and inappropriate to begin mass vaccinating populations with a fast-tracked vaccine with little or no testing or post-marketing surveillance in the majority of the target population, and especially the under-18’s. The only parties who stand to gain sign ificantly from this vaccination programme at present are the vaccine manufacturers and GPs surgeries who will receive a payment of £5.25 per dose of vaccine administered. GSK’s timing in relation to the ‘swine flu’ outbreak, as with Baxter, was all but perfect. The evidence contained in these Pandemrix vaccine documents is devastating. Before you inject yourself or members of your family to enrich GlaxoSmithKline and the doctors, read it. One Click Note: To the vasty majority of elected UK politicians subscribed to the One Click News Alerts, you will never be able to say that you were not warned.
Lara, Health Advocate
Related Links:
* GlaxoSmithKline 'Pandemic' Flu Vaccines Patent
GlaxoSmithKline Biologicals, September 2006
* CHMP Assessment Report For Pandemrix
European Medicines Agency
* Product Report, Pandemrix Vaccine
European Medicines Agency
60 million doses GlaxoSmithKline’s ‘Pandemrix’ H1N1 Swine Flu vaccine are shortly to be let out of the box and guinea pig trialled on the UK population including babies as young as 6 months and pregnant women. One Click publishes GSK's Pandemrix Vaccine Patent filed in 2006, together with the vaccine's CHMP Report and Product Information. These show that largely untested and untrialled, the vaccine contains the thimerosal and squalene adjuvants over which much concern has been raised. Serious adverse events on this vaccine were reported but not detailed. To date there have only been 80 swine-flu related deaths in the UK in 2009 and in general, symptoms are not severe. It is irresponsible, unsafe and inappropriate to begin mass vaccinating populations with a fast-tracked vaccine with little or no testing or post-marketing surveillance in the majority of the target population, and especially the under-18’s. The only parties who stand to gain sign ificantly from this vaccination programme at present are the vaccine manufacturers and GPs surgeries who will receive a payment of £5.25 per dose of vaccine administered. GSK’s timing in relation to the ‘swine flu’ outbreak, as with Baxter, was all but perfect. The evidence contained in these Pandemrix vaccine documents is devastating. Before you inject yourself or members of your family to enrich GlaxoSmithKline and the doctors, read it. One Click Note: To the vasty majority of elected UK politicians subscribed to the One Click News Alerts, you will never be able to say that you were not warned.
Lara, Health Advocate
Related Links:
* GlaxoSmithKline 'Pandemic' Flu Vaccines Patent
GlaxoSmithKline Biologicals, September 2006
* CHMP Assessment Report For Pandemrix
European Medicines Agency
* Product Report, Pandemrix Vaccine
European Medicines Agency
Reply all
Reply to author
Forward
0 new messages